Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that 57.4% of children under 10 with early-onset alopecia areata experienced over 50% hair regrowth after treatment with topical corticosteroids, noting that those under 4 showed significantly better responses, although personal atopic history was the only differing prognostic factor.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This review discusses frontal fibrosing alopecia and reports no clinical results; the authors note that no therapeutic options tested, including corticosteroids, finasteride, and minoxidil, have shown clear benefits.

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.

This study found fractional carbon dioxide laser therapy effective in treating alopecia areata, both alone and with topical treatments, suggesting decorin's involvement in improving hair growth.

This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.

This article reviews the diagnosis and treatment of clinical hair loss without providing new clinical results.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

The document concludes that different types of hair loss have specific treatments, and early diagnosis is crucial for preventing permanent hair loss.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This review explores the connection between psoriasis and hair loss, noting that both the disease and its treatments can contribute to alopecia, and reports no new clinical results.

Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.

This article reviews management strategies and interventions for common hair loss disorders in men and women, highlighting the psychological impact and emphasizing gender-specific approaches, but reports no new clinical results.

This chapter reviews the prevalence, pathogenesis, and management of hair and scalp disorders but reports no new clinical findings.

This review updated the evidence on various treatments for alopecia areata, finding that minoxidil and high potency corticosteroids showed significant results in patchy AA, but the overall evidence quality was low.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

This review examines the use of microneedles for treating alopecia areata, highlighting their ability to enhance drug delivery through the skin by bypassing the outer barrier and promoting hair growth with minimal invasiveness.

This review suggests that 308 nm excimer therapy may offer a well-tolerated non-pharmacologic option for alopecia areata, with more limited evidence for its effectiveness in lichen planopilaris and frontal fibrosing alopecia.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This review explored recent research on the immune mechanisms and potential therapeutic targets for alopecia areata, highlighting the roles of immune-related cells, autocrine and paracrine signaling, as well as factors like adipose-derived stem cells and gut microbiota in disease pathogenesis.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

This study involved 69 hair experts using a Delphi process to achieve consensus on treating frontal fibrosing alopecia, finding strong agreement on disease monitoring but less on physical and systemic therapies, indicating the need for more research.

Healthcare access for alopecia areata in the USA is unequal among ethnic groups.

This study reviews the use of lasers and light therapies as treatment options for managing the two most common types of alopecia—androegenetic alopecia and alopecia areata—highlighting that existing FDA-approved drugs like minoxidil and finasteride are partially effective, necessitating additional therapeutic approaches.

This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.

This study reported that atypical variants of alopecia areata made up less than 25% of all cases in their specialized trichology unit, suggesting a potential selection bias.

This article discusses a case of patchy alopecia areata that spares greying hairs but reports no new findings; it refers to existing literature for context.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.